Rezlidhia Now Available for Relapsed/Refractory AML With IDH1 Mutation
Rezlidhia (olutasidenib) is now available for the treatment of adults with relapsed or refractory acute myeloid leukemia and a susceptible IDH1 mutation.
Diagnosis & Disease Information
Salvage Chemotherapy Before Allo-HSCT Does Not Improve Outcomes in Rel/Ref AML
Salvage chemotherapy before allogeneic transplant does not improve outcomes in relapsed/refractory acute myeloid leukemia, a phase 3 study suggests.
Less May Be More When Treating Newly Diagnosed AML
Neither a higher dose of daunorubicin nor a second induction cycle improved outcomes in fit patients with newly diagnosed acute myeloid leukemia.
Triplet Deemed Effective in Newly Diagnosed AML but Not Relapsed/Refractory Disease
Combination magrolimab, azacitidine, and venetoclax appears effective in patients with newly diagnosed acute myeloid leukemia.
Triplet Appears Active in Relapsed/Refractory and Newly Diagnosed AML
Pivekimab sunirine plus azacitidine and venetoclax has demonstrated activity in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia.
Rezlidhia Approved for Relapsed/Refractory AML With IDH1 Mutation
The FDA has approved Rezlidhia (olutasidenib) to treat patients with IDH1-mutated, relapsed or refractory acute myeloid leukemia.
Adding Gilteritinib to Azacitidine Does Not Improve OS, EFS in Newly Diagnosed AML
Adding gilteritinib to azacitidine did not improve survival outcomes in patients with newly diagnosed, FLT3-mutated acute myeloid leukemia.
Pediatric Cancer Survivors Experience Premature Aging
Young adult survivors of pediatric cancer experience significant premature aging, a retrospective study suggests.
Azacitidine Maintenance Confers Benefits in AML Regardless of FLT3, NPM1 Status
Oral azacitidine improved survival independent of NPM1 or FLT3 mutational status, cytogenetic risk, or MRD status after chemotherapy.
Racial Disparities Identified in AYA Patients With Acute Myeloid Leukemia
Among AYAs with AML, Black patients experience higher rates of early death and lower rates of overall survival than White patients.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...